Bristol Myers Squibb said its GPRC5D-directed CAR T arlocabtagene autoleucel delivered notable improvements in its QUINTESSENTIAL Phase 2 study for heavily pretreated relapsed and refractory multiple myeloma. Analysts said the result is a “key derisking event,” with BMS also positioning the therapy for quadruple-class–exposed patients. The open-label, single-arm trial enrolled patients exposed to four prior lines, including a BCMA-targeting therapy. While BMS did not publish full data in its initial release, it indicated results will be shared at an upcoming congress; the program is also under FDA review with a target action date of Dec. 23.